Viva in Vitro Projects
Sepsis is the leading cause of hospital death. According to the WHO, sepsis affects more than 50 million people every year, causing the death of more than 11 million people. Almost half of them are children.
Viva In Vitro is focused on the development of its first compact hospital laboratory device for the rapid diagnosis and accurate prognosis of abdominal sepsis as the leading cause of hospital mortality, human suffering, resource consumption and expenditure in Intensive Care Units (ICU). But it does not renounce to collaborations, out-licensing or joint developments together with pharmaceutical companies or medical device manufacturers for the development of novel therapies or diagnostic devices in various indications.
Evolution. Viva In Vitro is the first technology-based company (EBT) of the Murcian Institute of Biosanitary Research Virgen de la Arrixaca (IMIB) Viva in Vitro
The beginnings of the company Viva in vitro founders, Joaquín Gómez Moya and Prof. Pablo Pelegrín, started collaborating professionally in a program assessing research projects.
Reducing sepsis mortality: the company Viva In Vitro Diagnostics, promoted by Vincle Capital, is getting one step closer to its goal
Sepsis is the leading cause of hospital mortality as it causes around eleven million deaths a year. It also implies an unparalleled economic burden due